In a further development of the collaboration between QCMD and RNAssist, QCMD will use the universal biological sample stabilization virusPHIX-P9™ as the matrix within its forthcoming SARS-CoV-2 antigen EQA pilot scheme. Studies have proven that virusPHIX-P9™ is both capable of inactivating SARS-CoV-2 as well as stabilizing clinical samples at ambient temperatures. Extensive testing at QCMD… Poursuivre la lecture QCMD to use RNAssist’s virusPHIX-P9™ Biomolecule Stabilization Technology in its SARS-CoV-2 antigen EQA scheme.
We are proud to have provided RNAssist reagents to the laboratory of Dr. Fay Betsou and Dr. Lorie Neuberger-Castillo at the Integrated Biobank of Luxembourg (IBBL) and pleased to report the publication of its use in the BIOPRESERVATION AND BIOBANKING Journal that sets out the analysis of the human microbiome using 16S NGS. We are… Poursuivre la lecture RNAssist stabilisation reagents published in the Biopreservation and Biobanking Journal (2019) for microbiome analysis
Published in Science 369, 1128-32 (2020) We are proud to have provided vivoPHIX™ to Gianmarco Raddi at the Sanger Institute and congratulate him for his cutting edge pre-print using our reagent. Insect hemocytes are the functional equivalents of leukocytes and limit the capacity of mosquitoes to transmit human pathogens through phagocytosis, encapsulation, secretion of immune… Poursuivre la lecture vivoPHIX™ in groundbreaking scRNA-seq Science publication by Dr. G. Raddi (Sanger Institute)
RNAssist and Rapid Labs Agree on Manufacturing and Supply Agreement for genoPHIX™ and vivoPHIX™ Biomolecule Stabilisation, Tissue Fixation and Microbial Inactivation Technology. Cambridge and Colchester, UK. 22nd January 2020 RNAssist (www.RNAssist.com) has developed several universal biological sample stabilisation, fixation and microbial inactivation reagents. Rapid Labs (www.rapidlabs.co.uk) a manufacturer and supplier of medical and veterinary diagnostic reagents, announced… Poursuivre la lecture RNAssist announces new manufacturing & supply agreement with Rapid Labs
Cambridge and Glasgow, UK. 23rd January 2020 – RNAssist. (www.RNAssist.com) a UK company that has developed a universal biological sample stabilization, fixation and inactivation reagent for clinical diagnostic and research applications, and QCMD (www.qcmd.org) specialised in molecular infectious disease proficiency testing, announced today an agreement under which RNAssist will license its vivoPHIX™ technology to QCMD. QCMD… Poursuivre la lecture RNAssist Limited and QCMD Agree Collaboration for vivoPHIX™ Biomolecule Stabilization Technology